摘要
背景:从过去十年到现在,有关脑瘤中O-(2-[18F]氟乙基)-L-酪氨酸(18F-FET)正电子发射断层扫描(PET)的研究已在文献中发表。aure[地名] [法国] 欧尔河 目的:根据近期文献资料,综述18F-FETPET在脑肿瘤中的最新进展和作用。 方法:介绍近期发表的有关18F-FETPET在神经肿瘤学中的作用的主要研究成果。 结果:18F-FETPET可用于脑肿瘤与非肿瘤性病变及低、高级别胶质瘤的鉴别诊断。18F-FETPET在外科手术中的应用计划允许更好地划定切除范围以外的边缘可见标准MRI。在活检计划方面,18F-fET PET对于鉴别NO内的恶性病灶特别有用。增强对比的胶质瘤。18F-FETPET可改善胶质瘤放射治疗计划。这种代谢显像方法可用于评价脑卒中患者的治疗反应。它提高了对脑肿瘤复发和治疗后变化的鉴别诊断。18F-FETPET可为高级别胶质瘤提供有用的预后信息。 结论:根据近期文献资料,18F-FET PET可提供比标准MRI更多的神经肿瘤学诊断信息。
关键词: PET,O-(2-[18F]氟乙基)-L-酪氨酸,FET,神经肿瘤学,神经影像学,胶质瘤,脑肿瘤,胶质母细胞瘤。
Current Medicinal Chemistry
Title:Recent Developments of 18F-FET PET in Neuro-oncology
Volume: 25 Issue: 26
关键词: PET,O-(2-[18F]氟乙基)-L-酪氨酸,FET,神经肿瘤学,神经影像学,胶质瘤,脑肿瘤,胶质母细胞瘤。
摘要: Background: From the past decade to date, several studies related to O-(2- [18F]fluoroethyl)-L-tyrosine (18F-FET) positron emission tomography (PET) in brain tumours have been published in the literature.
Objective: The aim of this narrative review is to summarize the recent developments and the current role of 18F-FET PET in brain tumours according to recent literature data.
Methods: Main findings from selected recently published and relevant articles on the role of 18F-FET PET in neuro-oncology are described.
Results: 18F-FET PET may be useful in the differential diagnosis between brain tumours and non-neoplastic lesions and between low-grade and high-grade gliomas. Integration of 18F-FET PET into surgical planning allows better delineation of the extent of resection beyond margins visible with standard MRI. For biopsy planning, 18F-FET PET is particularly useful in identifying malignant foci within non-contrast-enhancing gliomas. 18F-FET PET may improve the radiation therapy planning in patients with gliomas. This metabolic imaging method may be useful to evaluate treatment response in patients with gliomas and it improves the differential diagnosis between brain tumours recurrence and posttreatment changes. 18F-FET PET may provide useful prognostic information in high-grade gliomas.
Conclusion: Based on recent literature data 18F-FET PET may provide additional diagnostic information compared to standard MRI in neuro-oncology.
Export Options
About this article
Cite this article as:
Recent Developments of 18F-FET PET in Neuro-oncology, Current Medicinal Chemistry 2018; 25 (26) . https://dx.doi.org/10.2174/0929867325666171123202644
DOI https://dx.doi.org/10.2174/0929867325666171123202644 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Realizing the Potential of Blueberry as Natural Inhibitor of Metastasis and Powerful Apoptosis Inducer: Tapping the Treasure Trove for Effective Regulation of Cell Signaling Pathways
Anti-Cancer Agents in Medicinal Chemistry Ribozymes, DNAzymes and Small Interfering RNAs as Therapeutics
Current Drug Targets Extracellular Proteases as Targets for Drug Development
Current Protein & Peptide Science Genome and Transcriptome Analysis of Neuroblastoma Advanced Diagnosis from Innovative Therapies
Current Pharmaceutical Design The Mechanism of Action of Salsolinol in Brain: Implications in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Synthesis and Evaluation of Heterocycles Based Chalcone Derivatives as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Pharmacophore Development and SAR Studies of Imidazoline Receptor Ligands
Mini-Reviews in Medicinal Chemistry Bioactive Triterpenic Acids: From Agroforestry Biomass Residues to Promising Therapeutic Tools
Mini-Reviews in Organic Chemistry Nanoparticle- and Liposome-carried Drugs: New Strategies for Active Targeting and Drug Delivery Across Blood-brain Barrier
Current Drug Metabolism In Vivo Anticancer Activity, Toxicology and Histopathological Studies of the Thiolate Gold(I) Complex [Au(Spyrimidine)(PTA-CH<sub>2</sub>Ph)]Br
Anti-Cancer Agents in Medicinal Chemistry AKT-pathway Inhibition in Chronic Lymphocytic Leukemia Reveals Response Relationships Defined by TCL1
Current Cancer Drug Targets Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers
Current Drug Targets Microdialysis as an Excellent Sampling Approach for Biomedical Analysis
Current Pharmaceutical Analysis Telomerase Modulation in Therapeutic Approach
Current Pharmaceutical Design LRRC4 Inhibits Glioma Cell Growth and Invasion Through a miR-185- Dependent Pathway
Current Cancer Drug Targets Isomers of 4-[<sup>18</sup>F]fluoro-proline: Radiosynthesis, Biological Evaluation and Results in Humans Using PET
Current Radiopharmaceuticals LAT1 Targeted Delivery of Methionine Based Imaging Probe Derived from M(III) Metal Ions for Early Diagnosis of Proliferating Tumours using Molecular Imaging Modalities
Current Cancer Drug Targets STAT3 Regulation of Glioblastoma Pathogenesis
Current Molecular Medicine Angiogenesis and Hypoxia in Glioblastoma: A Focus on Cancer Stem Cells
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Advances with microRNAs in Tumorigenesis and Cancer Therapy)
Current Pharmaceutical Design